SHANGHAI, CHINA ------ In Dec. 16th, 2020, the Shanghai Biomedical Industry Equity Investment Fund (hereinafter referred to as "Shanghai Biomedical Fund"), which is approved by the Shanghai Municipal Government and initiated by Shanghai Industrial Investment Holdings was launched in Shanghai. Viva Biotech attended the ceremony and signed the cooperation agreement, to jointly build the Shanghai Biomedical Innovation Achievement Transformation Platform.
Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D, actively cooperate with transformation platforms, and provide all-round medical R&D support including but not limited to CRO/CDMO/CMO services, investment incubation services, site and equipment for continuous development of scientific research results.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us